Vusolimogene Oderparepvec
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Vusolimogene Oderparepvec, covering 2026-03-17 to 2026-03-17. Get the full timeline:
Most recent: Clinical Trial Update: Intratumoral Vusolimogene Oderparepvec (VO) in Combination With Pembrolizumab for Angiosarcoma [Phase 2]